You and your company team will be competing against other biotech firms to win the coveted BioBowl Trophy and bragging rights!
…Until next year
Date: Thursday, October 10th, 2019 Time: 4:00 – 6:30 PM (TBC) Location: Bowlmor – 15720 Shady Grove Rd, Gaithersburg, MD 20877
Invitation to follow.
Hosted by BioHealth Innovation and AstraZeneca
“Top 3 By 2023” has been the slogan for the Biohealth Capital Region (BHCR) over the past few years adopted by many economic development and industry leaders across Maryland, DC, and Virginia.
After more than four years of organized effort across the BHCR, starting with the first Regional Biotech Forum back in 2015, there is a clearly defined strategy underway and substantial progress is being made towards achieving that goal.
In this year’s GEN Top 10 report, Alexandria Real Estate Equities executive chairman and founder Joel Marcus was quoted about what factors will most likely drive the future creation of clusters for biopharma and other emerging life sciences.
“Clusters takeabout a generation, 25 years, to really evolve and develop,” stated Marcus, emphasizing the importance of thinking long-term for building a strong cluster.
The New Orleans BioInnovation Center is the only organization dedicated solely to advancing life science entrepreneurship through technology commercialization in Louisiana. The Center works closely with local academic institutions and other economic development entities to help develop cutting edge research, curate pilot projects with healthcare providers, and attract necessary complementary funding.
MADISON, Wis.–(BUSINESS WIRE)–Redox today announced its third annual Healthcare Interoperability Summit, which will take place on Oct. 15, 2019 at the Aloft Boston Seaport Hotel. The conference brings together the most influential health IT professionals from around the country for a deep dive into one of the biggest barriers to innovation in health IT today – interoperability.
One of the largest research contracts ever awarded to the University of Maryland School of Medicine (UMSOM) was announced by the National Institute of Allergy and Infectious Diseases (NIAID) this week, to the potential tune of more than $200 million over the next seven years.
Initially, the award will take the form of a $2.5 million contract to conduct clinical testing of influenza vaccines. It could be extended from there to up to $201 million. The research will be led by Dr. Kathleen Neuzil, a professor of Medicine and Pediatrics, director of the Center for Vaccine Development and Global Health (CVD) and the only U.S. member of the World Health Organization’s Strategic Advisory Group of Experts on Immunization. Her research will cover the testing of improved seasonal influenza vaccines and conducting controlled human influenza challenge studies with the hopes of creating a universal vaccine for use against emerging influenza strains and improving current seasonal vaccines.
Partners HealthCare is a global leader in healthcare research and development, with an immense capacity for innovation.
Partners HealthCare Innovation is the system’s business development arm that commercializes the insights and discoveries of researchers and clinicians at Boston-based Massachusetts General Hospital, Brigham and Women’s Hospital, Massachusetts Eye and Ear, and McLean Hospital, all of which are Harvard Medical School affiliates. The 125-member team was responsible for $154 million in commercial and investment income last year and at any given time is working on 2,000-plus active agreements.
Herndon, VA, Sept. 25, 2019 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) announced today the Commonwealth Research Commercialization Fund (CRCF) Request for Proposals (RFP) for FY2020.
The CRCF accelerates Virginia’s economic growth by supporting high-potential technology commercialization projects at Virginia’s public and private institutions of higher education, technology companies, and federal labs and nonprofit research organizations. A single solicitation for approximately $2.5 million will be offered in FY2020, through five programs: Commercialization, SBIR Matching Funds, STTR Matching Funds, Eminent Researcher Recruitment, and Matching Funds.
The product would reverse the effects of chemicals that disrupt nerve function for military and other emergency situations.
Image: Bob Kramer is president and CEO of Emergent BioSolutions. COURTESY EMERGENT BIOSOLUTIONS
